This content is in French.
Serum: a key to better treating IBD ?
21 février 2025
#IBD #CrohnsDisease #Biomarker #Gastroenterology #Metabolomics #Lipidomics
Chronic inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are digestive disorders affecting millions worldwide. These conditions are characterized by persistent inflammation of the digestive tract, occurring in flare-ups interspersed with periods of remission. While their exact causes remain unknown, genetic factors, microbiota imbalances, and excessive immune responses are suspected.
Chronic inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are digestive disorders affecting millions worldwide. These conditions are characterized by persistent inflammation of the digestive tract, occurring in flare-ups interspersed with periods of remission. While their exact causes remain unknown, genetic factors, microbiota imbalances, and excessive immune responses are suspected.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Tews, H. C., et al. (2024). Unique Metabolomic and Lipidomic Profile in Serum From Patients With Crohn’s Disease and Ulcerative Colitis Compared With Healthy Control Individuals. Inflammatory Bowel Diseases, 30(12), 2405-2417
View the source
